Article

Not Enough Cancer Drugs, Too Many Price Controls

Cancer patients face daunting challenges, including side effects of treatment, impact on family life and work disruptions. They now face another problem: shortages of vital drugs.

Imagine an oncologist talking to his patient: Everything is going well with your treatment, he says, but one of the drugs you've been receiving is unavailable. There's a substitute—sort of. Your Medicare copayment for the drug we've been using is $9. Now it will cost you $520 each time the substitute is given.

Read the full story: http://on.wsj.com/SQoOVB

Source: The Wall Street Journal

Related Videos
Screenshot of Adam Colborn, JD during an interview
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo